Evidence map›Paper›PMID 34721024›Full record

ArticleFrontiers in pharmacology2021

β-Adrenergic Receptor Inhibitor and Oncolytic Herpesvirus Combination Therapy Shows Enhanced Antitumoral and Antiangiogenic Effects on Colorectal Cancer.

Jiali Hu, Cuiyu Chen, Ruitao Lu, Yu Zhang, Yang Wang, Qian Hu, Wanting Li, Shiyu Wang, Ouyang Jing, Hanying Yi and 7 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in pharmacology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.4field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 13 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Review
  5. Article
  6. Review
  7. Review
  8. Review
  9. Oncolytic Viruses: Immunotherapy Drugs for Gastrointestinal Malignant Tumors.Frontiers in cellular and infection microbiology · 2022
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 6 institutions in 1 country.

Jiali HuDepartment of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha, China.
Cuiyu ChenDepartment of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha, China.
Ruitao LuSchool of Basic Medical Sciences, Guangzhou Medical University, Guangzhou, China.
Yu ZhangDepartment of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha, China.
Yang WangDepartment of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha, China.
Qian HuDepartment of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha, China.
Wanting LiDepartment of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha, China.
Shiyu WangDepartment of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha, China.
Ouyang JingDepartment of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha, China.
Hanying YiDepartment of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha, China.
Wei ZhangDepartment of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha, China.
Ling ChenDepartment of Gastrointestinal Surgery, Xiangya Hospital, Central South University, Changsha, China.
Weihua HuangDepartment of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha, China.
Jia LuoDepartment of Hepatobiliary and Intestinal Surgery, Hunan Cancer Hospital, Changsha, China.
Howard L McLeodDepartment of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha, China.
Ran XuDepartment of Urology, The Second Xiangya Hospital of Central South University, Changsha, China.
Yijing HeDepartment of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha, China.
Central South University · CNPharmacoGenetics (China) · CNXiangya Hospital Central South University · CNGuangzhou Medical University · CNHunan Cancer Hospital · CNSecond Xiangya Hospital of Central South University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Oncolytic viruses (OVs) are considered a promising therapeutic alternative for cancer. However, despite the development of novel OVs with improved efficacy and tumor selectivity, their limited efficacy as monotherapeutic agents remains a significant challenge. This study extended our previously observed combination effects of propranolol, a nonselective

Indexed as

antiangiogenesisapoptosiscolorectal canceroncolytic viruspropranolol

Identifiers

PMID34721024
PMCPMC8554205
OpenAlexW3212051464

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.